INVESTORS & MEDIA
News Release
Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to consistently translate science into medicine has led to six
Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® which yields optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contacts Regeneron: |
|
Media Relations |
Investor Relations |
Arleen Goldenberg |
|
Tel: + 1 (914) 847-3456 |
Tel: +1 (914) 847-5126 |
Mobile: +1 (914) 260-8788 |
|
View original content:http://www.prnewswire.com/news-releases/accessing-the-regeneron-second-quarter-2017-financial-and-operating-results-webcast-300499071.html
SOURCE
News Provided by Acquire Media